Roche breast cancer drug combo cuts death rate and recurrence
Roche breast cancer drug, Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy has been demonstrated in a phase 3 trial to have cut the risk of disease recurrence besides increasing the life span of patients with an aggressive form of early breast cancer.
Roche Breast Cancer Trial APHINITY Results
The breast cancer drug combination which met the primary endpoint was trialed as an adjuvant therapy post cancer surgery against the treatment of Herceptin (trastuzumab) and chemotherapy in the phase 3 study named APHINITY.
Sandra Horning, MD, Chief Medical Officer and Head of Global Product Development at Roche on the positive findings of the phase 3 trial of the breast cancer drug cocktail, said: “These results from the positive APHINITY study represent an important addition to the body of data for Perjeta in the treatment of people with HER2-positive early breast cancer.
“We look forward to discussing these adjuvant results with global regulatory authorities.”
“APHINITY provides yet another example of the importance of industry-academic collaborations and their value in advancing cancer care for people affected by this challenging disease”, said Gunter von Minckwitz, MD, study coordinator from the Breast International Group and academic study partners.
As per the phase 3 findings, the adjuvant treatment by a combination of Perjeta (pertuzumab) with Herceptin and chemotherapy administered post surgery had significantly brought down the risk of both the recurrence of breast cancer as well as death in comparison to Herceptin and chemotherapy alone.
The phase 3 trial of the breast cancer drug breast cancer drug combination was carried out in 4,805 patients with HER2-positive early breast cancer (eBC) that could be operable.
As per Roche, the Perjeta-based regimen’s safety profile was on par with what was seen in the previous trials with no new safety signals arising.
Perjeta, in combination with Herceptin and chemotherapy, is a licensed neoadjuvant therapy prior to surgery for HER2-positive eBC patients in over 75 countries after getting approvals for the same from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).
If the breast cancer drug combination is approved by the FDA and EMA, then it becomes a complete treatment for HER2-positive early breast cancer covering both pre and post surgeries.
Roche Breast Cancer Drug Perjeta Mechanism of Action
Roche’s breast cancer drug Perjeta acts on the HER2 receptor, a protein that is in excessive quantities on the exterior of cancer cells of HER2-positive cancer patients.
The breast cancer medicine prevents the HER2 receptor from pairing with other HER receptors on the cell surface which is believed to promote tumour growth and its survival.